12:50 PM - 1:10 PM ET
Scaling allogeneic CAR-T: A new era for cell therapy
For all its promise, autologous CAR-T has remained out of reach for most patients — limited by manufacturing timelines, serious toxicities, and the specialized infrastructure required to deliver it. Allogeneic approaches are now making a direct challenge to that model. Off-the-shelf availability, a more manageable safety profile, and the ability to scale manufacturing could together shift where and how cell therapy gets delivered. In this session, Zachary Roberts, EVP of Research & Development and Chief Medical Officer at Allogene Therapeutics, makes the case for why allogeneic CAR-T may define the next phase of the field — and what broader access could actually look like.